Ad-hoc | 6 August 2003 08:54

Evotec OAI AG english

Evotec OAI Appoints Bernard Questier Chief Business Officer Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high- value-added drug discovery to the pharmaceutical and biotechnology industries, today announced the appointment of Bernard Questier as Chief Business Officer. Bernard Questier, 49, will join Evotec OAI with effect from 6 October 2003. Being based in the Company’s headquarter in Hamburg, Germany, he will lead Evotec OAI’s business development functions as a member of the Management Board. Mr. Questier brings more than 20 years’ of international experience in various management positions. He is joining Evotec OAI following a successful career in Ventana Medical Systems, where he was responsible for most of the company’s business outside the United States. Bernard Questier has a Bachelor degree in chemistry from Hoger Technisch Instituut, Oostende, Belgium. Joern Aldag, President and Chief Executive Officer of Evotec OAI, said: “We look forward to Bernard Questier joining Evotec OAI. As a powerful individual and outspoken communicator with an international career that led him through convincing growth in various positions, he has all the necessary skills to further expand Evotec OAI’s position in the drug discovery and development market.” Contact: Anne Hennecke, Investor Relations & Corporate Communications, phone: +49-40-56081-286, anne.hennecke@evotecoai.com end of ad-hoc-announcement (c)DGAP 06.08.2003 ——————————————————————————– WKN: 566480; ISIN: DE0005664809; Index: TecDAX, NEMAX 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 060854 Aug 03